For atopic dermatitis, the hydrogel is designed to directly treat the immuno-inflammatory component. Credit: Gabdrakipova Dilyara / Shutterstock.com.

Alphyn Biologics has completed $25m in a Series B funding round to support the global Phase IIb trial of its lead candidate, Zabalafin Hydrogel, for atopic dermatitis (AD).

The proceeds will also support the initiation of a second Phase II clinical programme for molluscum contagiosum virus (MCV) and expand the drug raw material supply.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

QCA Investment Group spearheaded the twice-oversubscribed round, which saw participation from existing and new investors.

Zabalafin Hydrogel is under development as a treatment targeting the interconnected drivers of AD, including itch, inflammation, dry skin, and bacteria.

The drug is also being investigated for its potential to address the virus, inflammation, itch, dermatitis, and bacterial infection associated with MCV.

According to Alphyn, Zabalafin Hydrogel is expected to offer sustained management along with long-term control of these conditions.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The company noted that, for MCV, the hydrogel could become the first direct antiviral drug that is both effective and safe, offering a new treatment option for paediatric patients affected by the condition.

For AD, Zabalafin Hydrogel is designed to directly treat the immuno-inflammatory component, pruritus, bacterial involvement, and xerosis.

Alphyn Biologics CEO Neal Koller said: “We are incredibly grateful for the support of our current and new investors. This financing reflects their confidence in our multi-target therapeutic drug platform and our unique and highly differentiated drug candidates for atopic dermatitis and the molluscum contagiosum virus.

“We are well-positioned to rapidly advance Zabalafin Hydrogel towards our next key milestones – two pivotal Phase III trials – while broadening our pipeline of breakthrough therapies for skin diseases.”

The US-based company, which became operational in 2020, has subsidiaries in Austria and Australia, and has so far secured $34m.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact